



## Ad hoc release

### **STADA: Preliminary figures 2012 demonstrate successful financial year – dividend to increase by more than 35 percent**

Bad Vilbel, February 28, 2013 – On the basis of the preliminary figures for financial year 2012, today on February 28, 2013, the Executive Board of STADA Arzneimittel AG has taken a resolution on the dividend proposal for the past financial year. According to the proposal, the STADA Executive Board recommends that the Supervisory Board propose to the next Annual General Meeting on June 5, 2013 a dividend for financial year 2012 in the amount of Euro 0.50 per common share (previous year: Euro 0.37) and thereby 35.1 percent more than in the previous year. At the same time, the Executive Board has adopted a positive outlook for financial year 2013 and has confirmed the Group's long-term prognosis envisaged for 2014.

According to preliminary Group key figures, Group sales in 2012 are expected to have increased by 7 percent to Euro 1,837.5 million. All reported key earnings figures of the Group are expected to have recorded growth. Thereby, reported EBITDA is anticipated to have increased by 45 percent to Euro 323.8 million. EBITDA adjusted for one-time special effects is estimated to have risen by 9 percent to Euro 367.5 million and thereby reached a new record high in corporate history. Reported earnings per share are anticipated to have recorded an increase to Euro 1.46 (previous year: Euro 0.37). Adjusted for one-time special effects and non-operational effects from the measurement of derivative financial instruments, earnings per share are expected to be slightly above the level of the previous year with Euro 2.50 (previous year: Euro 2.49). In view of the investments made in larger acquisitions in financial year 2012, net debt is anticipated to have risen to Euro 1,177.3 million as of the balance sheet date (December 31, 2011: Euro 900.3 million). The net debt to adjusted EBITDA ratio is estimated to have amounted to 3.2 (previous year: 2.7). As compared to the figure in the first nine months of 2012, which was still at 3.6, a substantial improvement of this ratio was able to be made within a short period.

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller  
Chairman of the Supervisory Board: Dr. Martin Abend



In its overall assessment, the Executive Board, from today's perspective, expects further growth of sales and earnings of the Group for financial years 2013 and 2014. For adjusted EBITDA in financial year 2013, the Executive Board anticipates the opportunity for another increase in the high single-digit percentage area and therefore to achieve a new record figure. In addition, the Executive Board affirms the long-term prognosis envisaged for 2014, according to which Group sales of approximately Euro 2.15 billion, at an adjusted level, EBITDA of approximately Euro 430 million and net income of approximately Euro 215 million should be reached at minimum.

STADA's final business results for 2012 will be published on March 21, 2013.



### STADA Key Figures

	2012 (approx. figures)	2011	+/-
Group sales	Euro 1,837.5 million	Euro 1,715.4 million	+7%
EBITDA	Euro 323.8 million	Euro 223.2 million	+45%
<i>EBITDA, adjusted</i>	<i>Euro 367.5 million</i>	<i>Euro 337.2 million</i>	+9%
Net income	Euro 86.5 million	Euro 22.0 million	>100%
<i>Net income, adjusted</i>	<i>Euro 147.9 million</i>	<i>Euro 146.6 million</i>	+1%
Earnings per share	Euro 1.46	Euro 0.37	>100%
<i>Earnings per share, adjusted</i>	<i>Euro 2.50</i>	<i>Euro 2.49</i>	+0.4%

Additional information:

STADA Arzneimittel AG / Corporate Communications / Stadastraße 2–18 / 61118 Bad Vilbel /  
 Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail: [communications@stada.de](mailto:communications@stada.de)  
 Or visit us in the Internet at [www.stada.com](http://www.stada.com).

Executive Board: Hartmut Retzlaff (Chairman) / Helmut Kraft / Dr. Axel Müller  
 Chairman of the Supervisory Board: Dr. Martin Abend